Clinical Trials Flowcharts

August 2024
To refer a patient:

To learn more about a specific trial, contact the MOG leader listed, or call the clinical trials hotline at 319-353-8155.

All calls to the clinical trials hotline will be returned within 48 hours.

The clinical trials team will then work with you to get your patient enrolled, when appropriate.
Breast Cancer Trials

Sneha Phadke, DO, MPH
sneha-phadke@uiowa.edu

Praveen Vikas, MBBS
praveen-vikas@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**BREAST CANCER**

**ADJUVANT**

**HER 2**

**TRIPLE NEGATIVE**

- **Tropion**: completed 6 cycles of neoadjuvant therapy w/ anthracycline and/or taxane; residual invasive disease in the breast or axillary LN at resection; no evidence of locoregional or distant relapse  
  PI: Sneha Phadke  
  NCT05629585

- **Ascent05**: Adequate excision and surgical removal of all clinical evidence of disease in the breast and/or LN and have adequately recovered from surgery  
  PI: Praveen Vikas  
  NCT05633654

- **Optim-ICE**: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo + pembro x 6 cycles; < 12 weeks between surgery and randomization  
  PI: Sneha Phadke  
  NCT05812807

**ER +**

- **RAPHLRR**: Locoregional recurrence; adequate local treatment for locoregional recurrence; Enrolled within 6 mo of last local treatment  
  PI: Sneha Phadke  
  NCT05467891

- **Cambria**: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)  
  PI: Sneha Phadke  
  NCT05774951

- **BR009**: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26  
  PI: Sneha Phadke  
  NCT05879926

---

Clinical Trials Hotline: 319-353-8155
BREAST CANCER

METASTATIC TNBC

OBT076-001: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

PI: Yousef Zakharia

NCT04064359

Clinical Trials Hotline: 319-353-8155
**BREAST CANCER**

**METASTATIC HER2-**

- **C4391022**: ER + and/or PR +; must have received CDK4/6 + NSAI with documented PD during or after CDK4/6; measurable disease or non-measurable bone only disease as defined by RECIST1.1
  - PI: Praveen Vikas
  - [NCT06105632](https://clinicaltrials.gov/ct2/show/NCT06105632)

- **OBT076-001**: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
  - PI: Yousef Zakharia
  - [NCT04064359](https://clinicaltrials.gov/ct2/show/NCT04064359)

- **Olema**: ER + and PR +/−; no more than 2 prior lines for metastatic disease; no more than 1 line of chemo for advanced/metastatic disease
  - PI: Sneha Phadke
  - [NCT05508906](https://clinicaltrials.gov/ct2/show/NCT05508906)

**Clinical Trials Hotline**: 319-353-8155
BREAST CANCER

P-MUC1C-ALLO1-001: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

NCT05239143

NCT05935098

Clinical Trials Hotline: 319-353-8155
GI Cancer Trials

**Naomi Fei, MD, MS**
nami-fei@uiowa.edu

**Michael Hummel, MD**
michael-hummel@uiowa.edu

**Saima Sharif, MD, MS**
saima-sharif@uiowa.edu

**Mimi McKay, MPH, BSN**
Clinical Trial Navigator
marie-mckay@uiowa.edu

**Clinical Trials Hotline:** 319-353-8155
**PANCREATIC CANCER**

**ADJUVANT**

**AMPLIFY7P**
Criteria: Upfront resectable stage I, II, or III disease per current AJCC staging criteria, with radiographic NED (no evidence of disease) status within 6 months following completion of locoregional treatment

PI: Naomi Fei

NCT05726864

**NON-RESECTABLE**

**TIGER-PAC/RENOVO**
Criteria: Histo/ctyo confirmed diagnosis within 6 weeks of consent; no prior treatment for pancreatic cancer OR more than 1 cycle of gem delivery and nab-paclitaxel; no evidence of metastatic disease; arterial anatomy suitable of intraarterial of gemcitabine to intended tumor

PI: Naomi Fei

NCT05249101

**METASTATIC**

**CG-745-2-08**
Criteria: Locally advanced or metastatic pancreatic adenocarcinoma without evidence of progression on initial chemo for metastatic disease (CR, PR or SD); FOLFIRINOX at full or modified dose for a minimum of 16 wks with no evidence of progression

PI: Naomi Fei

NCT05249101

**P-MUC1C-ALL01-001:**
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALL01 in Adult Subjects With Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

NCT05239143

**BGB-A317-A3055-101:**
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

NCT05935098

---

Clinical Trials Hotline: 319-353-8155
COLORECTAL CANCER

**NEOADJUVANT**

- **Dostarlimab**
  - Criteria: Biopsy proven Stage II or III dMMR amenable to en block surgical resection; biopsy specimen has enough tissue for 4-6 FFPE slides; absence of metastatic disease
  - PI: Saima Sharif
  - NCT05239546

**ADJUVANT**

- **NRG-GI008**
  - Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing
  - PI: Saima Sharif
  - NCT05174169

**METASTATIC**

- **BXQ-350**
  - Criteria: Newly diagnosed stage IV metastatic adenocarcinoma of the colon/rectum; may not have mismatch repair deficiency or microsatellite instability status-high Stage IV colorectal cancer
  - PI: Saima Sharif
  - NCT0532590

- **BGB-A317-A3055-101**
  - A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
  - PI: Muhammad Furqan
  - NCT05935098

- **CODEBREAK**
  - Criteria: Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing
  - PI: Muhammad Furqan
  - NCT04185883

**KRAS G12C**

- **BGB-A317-A3055-101**
  - A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
  - PI: Muhammad Furqan
  - NCT05935098

- **CODEBREAK**
  - Criteria: Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing
  - PI: Muhammad Furqan
  - NCT04185883
GASTRIC/GASTROESOPHAGEAL CANCER

1L

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif
NCT05677490

METASTATIC

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan
NCT05935098

ACCRU GI-1810:
Criteria: LA, unresectable, metastatic disease that has progressed ≤ 180 days from last treatment, patient must have received 5-FU or capecitabine and platinum or trastuzumab in case of HER2+ disease

PI: Saima Sharif
NCT04660760

OBT076-001: A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors

PI: Doug Laux
NCT04064359

Clinical Trials Hotline: 319-353-8155
HEPATOCELLULAR CARCINOMA

ROUTE90:
Criteria: Confirmed diagnosis of HCC, LIRADS 5 or biopsy; One lesion ≥ 2 cm in diameter, no more than 3 lesions; Max 3 lesions and single lesion size ≤ 8 cm & sum tumor dimensions of ≤ 12 cm; Evidence that > 33% of the total liver volume is disease-free; No extra hepatic disease

PI: Michael Hummel

NCT05953337
GU Cancer Trials

Joseph Caster, MD, PhD
joseph-caster@uiowa.edu

Michael O’Donnell, MD
michael-odonnell@uiowa.edu

Bilal Rahim, MD
bilal-rahim@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
BLADDER CANCER

NMIBC

Adapt
Criteria: Histologically confirmed urothelial carcinoma of bladder (Ta, T1, or Tis) on TURBT; BCG unresponsive disease (persistent CIS with or without the presence of Ta or T1 tumors within 12 months of completion of BCG, or recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy

Bridge
Criteria: High-grade non-muscle invasive urothelial carcinoma of the bladder; must have all visible papillary tumor resected by the treating urologist at the site registering the patient; no prior intravesical therapy for bladder cancer with the exception of perioperative chemotherapy at the time of TURBT

NEOADJUVANT

EA8192
Criteria: High grade upper tract urothelial carcinoma proven by biopsy with 12 weeks of randomization; no component of small cell/neuroendocrine carcinoma; no evidence of metastatic disease or enlarged LN

VOLGA
Criteria: Muscle-invasive UC of the bladder; T2-T4aN0/1M0 or UC of the bladder with clinical stage T1N1M0; no prior systemic chemotherapy or immunotherapy for the treatment of MIBC or UC; medically fit for cystectomy; cisplatin ineligible; will receive Enfortumab Vedotin in combination

ADJUVANT

V940-005
Criteria: muscle-invasive urothelial carcinoma; high-risk pathologic disease after radical resection

NCT03317158
NCT05538663
NCT04628767
NCT04960709
NCT06305767

PI: Michael O'Donnell
PI: Michael O'Donnell
PI: Bilal Rahim
PI: Bilal Rahim
PI: Bilal Rahim

Clinical Trials Hotline: 319-353-8155
**BLADDER CANCER**

**BGB-A317-A3055-101**
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

PI: Muhammad Furqan
NCT05935098

**ACR-368-201**
Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen

PI: Emily Hill
NCT05548296

**ASP1012**
Criteria: histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

PI: Doug Laux
NCT06171178

**OBT076-001**
Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

PI: Doug Laux
NCT04064359
Clinical Trials Hotline: 319-353-8155

PROSTATE CANCER

**METASTATIC HORMONE SENSITIVE**

**S1802**
Criteria: Adenocarcinoma of prostate; no prior local therapy for prostate adenocarcinoma; evidence of metastatic disease on bone scan and CT or MRI; received no more than 28 weeks of standard systemic therapy (SST); no progression while on SST; must have surgically resectable disease per urology consult

PI: Joseph Caster

NCT03678025

**METASTATIC CRPC**

**Xmab®20717**
Criteria: Carcinoma of prostate; progressive mCRPC; progression after treatment with at least 2 prior lines of anticancer therapy approved for treatment of metastatic prostate cancer; subjects who did not have orchiectomy must be on androgen deprivation suppression treatment

PI: Bilal Rahim

NCT05005728

**ASP1012**
Criteria: histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

PI: Doug Laux

NCT06171178
**KIDNEY CANCER**

**LOCALLY ADVANCED/METASTATIC**

1L

- **SLM/Axitinib/Pembrolizumab**
  - Criteria: histologically and radiologically advanced or metastatic ccRCC; treatment naïve in metastatic setting; CNS mets excluded
  - PI: Bilal Rahim
  - NCT05363631

2L+

- **NKT2152-101**
  - Criteria: LA or metastatic ccRCC and progressed during treatment, are R/R and not amenable to curative therapy or standard therapy has progressed during treatment with at least 1 prior line; must take 6 min/400 m walking test; no known symptomatic brain mets; must not need supplemental oxygen or have pulse ox <95% at screening
  - PI: Bilal Rahim
  - NCT05119335
KIDNEY CANCER

**METASTATIC**

**BGB-A317-A3055-101**
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

PI: Muhammad Furgan

NCT05935098

**AB-2100-201**
Criteria: Must have received an immune checkpoint inhibitor and a VEGF-targeted therapy in the advanced or metastatic setting. Must have evidence of progression on or after the last treatment regimen or discontinued treatment for unacceptable toxicity

PI: Umar Farooq

NCT06245915

**ASP1012**
Criteria: histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

PI: Doug Laux

NCT06171178

**OBT076-001**
Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

PI: Doug Laux

NCT04064359

Clinical Trials Hotline: 319-353-8155
OVARIAN CANCER

LOW GRADE SEROUS CARCINOMA

NRG-GY019:
Criteria: Newly diagnosed, stage II-IV low-grade serous ovarian, fallopian tube and primary peritoneal cancers; must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (≤ 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) allowed; must enroll within 8 weeks of primary surgery

NCT04095364

HIGH GRADE SEROUS CARCINOMA

GOG-3078-GLORiosa (Maintenance therapy):
Criteria: Recurrent (1st recurrence), platinum-sensitive high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer; FRα-High; subjects who have not progressed after second-line platinum-based chemotherapy plus bevacizumab; prior PARP required if BRCA mutated; must be randomized within 8 weeks from last dose of platinum-based triplet therapy

Pt: David Bender

NCT05445778

Clinical Trials Hotline: 319-353-8155
OVARIAN CANCER

**METASTATIC**

**BGB-A317-A3055-101**
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

PI: Muhammad Furqan

NCT05935098

**ACR-368-201**
Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen

PI: Emily Hill

NCT05548296

**GOG-3087 NXP800-101**
Criteria: 1-5 prior systemic lines of therapy; prior bevacizumab required unless contraindicated due to history of bowel obstruction; prior PARP required if BRCA+

PI: David Bender

NCT05226507

**P-MUC1C-ALLO1-001**: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

NCT05239143

**IMC-F106C-101**: Criteria: HLA-A*02:01 positive; PRAME positive tumor; Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies

PI: Muhammad Furqan

NCT04262466
ENDOMETRIAL CANCER

NEWLY DIAGNOSED HER2+

NRG-GY026:
Criteria: stage IA-IVB, non-recurrent, chemo-naive, HER2+ endometrial serous carcinoma or endometrial carcinosarcoma; must have myoinvasive disease; must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration; no prior radiation therapy, biologic, or targeted therapy for endometrial cancer

PI: David Bender

NCT05256225

RECURRENT dMMR

NRG-GY025:
Criteria: Recurrent MMR-deficient endometrial cancer; serous and carcinosarcoma subtypes excluded; measurable or detectable disease required; patients may have received up to 2 prior lines of systemic therapy; prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings; must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition

PI: David Bender

NCT05112601

Clinical Trials Hotline: 319-353-8155

Clinical Trials
Open
Pending
Enrollment Hold
ENDOMETRIAL CANCER

METASTATIC

NRG-GY028
Criteria: Recurrent/metastatic grade 1 or 2 endometrioid endometrial cancer; measurable disease required; may have received unlimited prior lines of therapy; prior hormonal therapy (e.g., megestrol acetate, medroxyprogesterone acetate, aromatase inhibitor, tamoxifen, fulvestrant) it must have completed at least 6 months prior to registration; no prior AKT inhibitor

PI: David Bender

NCT05538897

ACR-368-201
Criteria: histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen

PI: Emily Hill

NCT05548296

OBTO76-001:
Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

PI: Doug Laux

NCT04064359

IMC-F106C-101:
Criteria: HLA-A*02:01 positive; PRAME positive tumor; Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies

PI: Muhammad Furqan

NCT04262466
CERVICAL CANCER

GOG3091: Recurrent/metastatic HPV16+, PD-L1+ who has progressed during or after first line standard of care; No prior therapeutic HPV16 vaccine

BGB-A317-A3055-101: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: David Bender

NCT06099418

PI: Muhammad Furqan

NCT05935098

Clinical Trials Hotline: 319-353-8155
GERM CELL TUMOR

LOW OR STANDARD RISK

AGCT1531:
Criteria: Low risk stage I immature teratoma (IT); site: ovarian; tumor markers: alpha-FP ≤ 1,000 ng/mL, beta-HCG institutional normal; all ages

Standard risk 2 (SR2)
Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 25

PI: David Dickens

NCT03067181

INTERMEDIATE OR POOR RISK

AGCT1532:
Criteria: Histologically or cytologically confirmed germ cell; or Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently; Primary arising in testis, ovary, retroperitoneum, or mediastinum; Intermediate or poor prognosis as defined by ISCCC classification

PI: David Dickens

NCT02582697

Clinical Trials Hotline: 319-353-8155
BRCA1 OVARIAN CANCER RISK REDUCTION

NRG-CC008:
Criteria: Individuals 35-50 years of age, inclusive; positive CLIA-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient; non-randomized prospective trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers; patient choice of bilateral salpingectomy or bilateral salpingo-oophorectomy (with or without hysterectomy); no prior radiation to the abdomen/pelvis; no prior hormonal therapy within 90 days

NCT04251052
Head & Neck Cancer Trials

Doug Laux, MD, MS
douglas-laux@uiowa.edu

Nitin Pagedar, MD, MPH
nitin-pagedar@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mcKay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**HEAD AND NECK CANCER**

**HNSCC**

- **NEWLY DIAGNOSED ORAL CAVITY**
  - NRG-HN006
    - Criteria: Pathologically proven SCC of oral cavity including tongue, FOM, mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, RMT, or hard palate; T1-2N0M0 AJCC 8th ed; must be candidate for sentinel lymph node biopsy and potential completion neck dissection or elective neck dissection
    - **PI: Nitin Pagedar**
    - **NCT: 04333537**

- **1L UNRESECTABLE OR METASTATIC**
  - Hookipa
    - Criteria: HPV 16+ cancer via genotype testing; eligible to receive pembrolizumab
    - **PI: Doug Laux**
    - **NCT: 04180215**

  - GSK-219885
    - Criteria: The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx; Subjects must not have had prior systemic therapy administered in the R/M setting
    - **PI: Doug Laux**
    - **NCT06062420**

**SALIVARY GLAND**

- BTCRC-HN17-111
  - Criteria: LA, recurrent, or metastatic salivary gland carcinoma not amenable to curative surgery or radiation; archival tissue must be available for central confirmation of androgen receptor-positive disease; any number of prior lines permitted but no prior anti-androgen therapy or immune checkpoint blockade permitted
  - **PI: Doug Laux**
  - **NCT: 03942653**
HEAD AND NECK CANCER

**BGB-A317-A3055-101**
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

**INBRX-106**
Criteria: Subjects must have LA or metastatic disease which is checkpoint inhibitor naïve

**TCTLR-101**
Criteria: Histologically confirmed SCC regardless of HPV or PD-L1 status; no more than 1 prior line of chemotherapy-based treatment for LA, unresectable, recurrent or metastatic disease; At least 1 lesion that is ≥15 mm in the longest diameter and is safely accessible for intratumoral injection

**ASP1012**: Histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

**CA052002**: A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

---

**PI**: Muhammad Furqan

**PI**: Muhammad Furqan

**PI**: Doug Laux

**PI**: Doug Laux

**PI**: Doug Laux

---

**NCT05935098**

**NCT04198766**

**NCT04799054**

**NCT06171178**

**NCT04895709**
**HEAD AND NECK CANCER**

---

**INBRX-106**
Criteria: Subjects must have LA or metastatic disease which is checkpoint inhibitor naïve

PI: Muhammad Furqan

NCT04198766

---

**BGB-A317-A3055-101**
Criteria: Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8

PI: Muhammad Furqan

NCT05935098

---

**ASP1012**
Criteria: Histologically, or cytologically, confirmed diagnosis of locally advanced or metastatic solid tumor

PI: Doug Laux

NCT06171178
NON-MELANOMA SKIN CANCER

CUTANEOUS SQUAMOUS CELL

V940-007
Criteria: Has LA Stage II-IV (M0) cSCC without distant metastases; cSCC must be amenable to surgery (resectable) with curative intent

NCT06295809

TCTLR-101
Criteria: Histologically confirmed SCC regardless of HPV or PD-L1 status; no more than 1 prior line of chemotherapy-based treatment for LA, unresectable, recurrent or metastatic disease; At least 1 lesion that is ≥15 mm in the longest diameter and is safely accessible for intratumoral injection

Pt: Doug Laux

NCT04799054

MERKEL, BASAL, SCC

RPL-001-16
Criteria: Locally advanced or metastatic NMSC not considered treatable by surgery; must have received 8 wks of anti-PD1/PDL1 as their last line of therapy and progressed while on treatment

Pt: Doug Laux

NCT: 03767348

MERKEL CELL

HCRN MCC20-443
Criteria: Histological or cytological evidence of Merkel cell cancer per AJCC, 8th ed; presence of somatostatin receptors by Ga-68 dotatate imaging; progress on treatment with anti-PD1/L1 administered either as monotherapy or in combination with other check point inhibitors or other therapies

Pt: Doug Laux

NCT: 05583708
Leukemia Trials

Gerk Sutamtewagul, MD
gerk-sutamtewagul@uiowa.edu

Clinical Trials Hotline: 319-353-8155

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu
ACUTE MYELOID LEUKEMIA (AML)

**NEWLY DIAGNOSED**

KO-MEN-007
Criteria: Newly diagnosed or relapsed/refractory AML with NPM1 or KMT2A rearrangement

PI: Gerek Sutamtewagul

NCT: 05735184

---

**RELAPSED/REFRACTORY**

KO-MEN-008
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PI: Gerek Sutamtewagul

NCT06001788

---

KO-MEN-007
Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib or the treatment of patients with acute myeloid leukemia

PI: Gerek Sutamtewagul

NCT: 05735184
CML

ASC2ESCALATE
Criteria: CML-CP, no previous AP or BC

Pf: Mario Sy

NCT05384587
MALIGNANT HEME (OTHER)

NEWLY DIAGNOSED MDS

SY-1425-301
Criteria: Must be RARA-positive based on investigational assay; diagnosis of MDS according to WHO classification and classified as very high, high, or intermediate risk per IPSS

PI: Grerk Sutamtewagul
NCT: 04797780

ANY MYELOID MALIGNANCY

CA055-001
Criteria: Moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria

PI: Grerk Sutamtewagul
NCT: 05209295
Lymphoma Trials

David Dickens, MD, FAAP
david-dickens@uiowa.edu

Umar Farooq, MD
umar-farooq@uiowa.edu

Eric Mou, MD
eric-mou@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
LARGE CELL LYMPHOMAS

SKYGLO
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

ANHL1931
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PI: Eric Mou
PI: David Dickens
PI: Brian Link

NCT: 06047080
NCT04759586
NCT01787409

Clinical Trials Hotline: 319-353-8155
LARGE CELL LYMPHOMAS

**MC200802**
Randomized Phase 2 Study With Safety Run-In of PD-1 Inhibitor and IgG4 SIRPa-Fc Fusion Protein (TTI-622) and PD-1 Inhibitor and IgG1 SIRPa-IgG4-Fc Fusion Protein (TTI-621) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

**PI:** Umar Farooq

**NCT:** 05507541

**ELM-2**
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

**PI:** Umar Farooq

**NCT:** 03888105

**ANTLER**
CRISPR-Edited Allogeic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma

**PI:** Umar Farooq

**NCT:** 04637763

**CRG-022-101**
A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma

**PI:** Umar Farooq

**NCT:** 05972720

**MPCT-012L**
Study of IMPT-314 (CD19/CD20 bispecific CAR-T) in R/R Aggressive B-cell NHL

**PI:** Umar Farooq

**NCT:** 05826535

**BGB-16673**
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

**PI:** Eric Mou

**NCT:** 05006716

**JNJ-90009530**
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

**PI:** Umar Farooq

**NCT:** 05784441

**SGN35T-001**
An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

**PI:** Eric Mou

**NCT:** 06120504

**Clinical Trials Hotline:** 319-353-8155
MANTLE CELL LYMPHOMA

FRONTLINE

A052101:
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients (Age ≥ 70 or ≥ 60 with selected comorbidities) with Mantle Cell Lymphoma

PI: Umar Farooq
NCT: 05976763

RELAPSED/REFRACTORY

ADI-20200101
GLEAN-1: A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies

PI: Umar Farooq
NCT: 04735471

BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou
NCT: 05006716

SGN35T-001:
An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou
NCT06120504
FOLLICULAR LYMPHOMA

SGN35T-001:
An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

Pl: Eric Mou
NCT06120504

JNJ-90009530
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Pl: Umar Farooq
NCT05784441

BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Pl: Eric Mou
NCT: 05006716

Clinical Trials Hotline: 319-353-8155
**CLL/SLL**

**FRONTLINE**

**BELLWAVE-011:**
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

**BGB-11417-301:**
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

**RELAPSED/REFRACTORY**

**BGB-16673**
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

**NCT06136559**

**NCT06073821**

**NCT: 05006716**

PI: Eric Mou

Clinical Trials Hotline: 319-353-8155
HODGKIN LYMPHOMA

**FRONTLINE**

AHOD2131:
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

PI: David Dickens
NCT05675410

**RELAPSED/REFRACTORY**

BTCRC HEM 15-027:
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

PI: Umar Farooq
NCT03681561

SGN35T-001:
An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou
NCT06120504
T-CELL LYMPHOMA

**FRONTLINE**

- **A051902:**
  A Randomized Phase II Study of CHOP(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative (<10%) Peripheral T-Cell Lymphomas
  - PI: Umar Farooq
  - NCT: 04803201
  - NCT01787409

- **Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency**
  - PI: Brian Link

**RELAPSED/REFRACTORY**

- **SGN35T-001:**
  An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies
  - PI: Eric Mou
  - NCT06120504

**Clinical Trials Hotline:** 319-353-8155
OTHER LYMPHOMAS

RELAPSED/REFRACTORY

Marginal Zone Lymphoma
ELM-2
A Study to Assess the Anti-Tumor Activity and Safety of Odronestamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

PI: Umar Farooq
NCT: 03888105

Marginal Zone Lymphoma
JNJ-90009530
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

PI: Umar Farooq
NCT05784441

Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
BGB-16673
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou
NCT: 05006716
Melanoma Trials

Asad Javed, MBBS
asad-javed@uiowa.edu

Yusuf Menda, MD
yusuf-menda@uiowa.edu

Mohammed Milhem, MBBS
mohammed-milhem@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
CUTANEOUS MELANOMA

**NEOADJUVANT**

**NeoDREAM**
Criteria: Stage IIIB/IIIC, resectable melanoma, with injectable metastasis (nodal, subcutaneous, cutaneous)
Investigational agent: Neoadjuvant Intratumoral injection of Daromun Immune therapy

**TCLTR-101**
Criteria: Resectable melanoma, with injectable metastasis (primary cutaneous or nodal metastasis)
Investigational agent: Neoadjuvant Intratumoral injection of Toll-like receptor agonists (TLR7/8)

**ADJUVANT**

**V940-001**
Criteria: Surgically resected diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma; has not received any prior systemic therapy for their melanoma beyond surgical resection; no more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
Investigational Agent: mRNA melanoma neoantigen vaccine plus pembrolizumab

**NCT03667889**
PI: Mohammed Milhem

**NCT04799054**
PI: Doug Laux

**NCT05933577**
PI: Mohammed Milhem

Clinical Trials Hotline: 319-353-8155
CUTANEOUS MELANOMA

LYL845-101
Criteria: Cutaneous melanoma refractory to PD1 therapy. Does not require prior BRAF therapy (if the tumor is BRAF V600 mutated. Treated CNS metastasis allowed

Investigational Agent: Tumor-infiltrating lymphocytes (TIL therapy)

PI: Asad Javed

NCT05573035

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma
Criteria: Advanced melanoma patients failing standard of care therapy. Includes uveal and mucosal melanoma cohorts. Successful screening radionucleotide scan required (done on study). Adequate renal and bone marrow function

Investigational Agent: Lead based, radio-pharmaceutic agent targeting MC1R receptor on melanoma tumor cells

PI: Yusuf Menda

NCT05555312
UVEAL MELANOMA

IDE196-002
Criteria: HLA-A*02:01 negative patients
(Testing can be done at U of Iowa)
Treatment naïve patients with metastatic uveal melanoma

Investigational Agent: Darovasertib + Crizotinib vs investigator choice

PI: Asad Javed

NCT05987332
Myeloma Trials

Hira Shaikh, MBBS  hira-shaikh@uiowa.edu

Christopher Strouse, MD  christopher-strouse@uiowa.edu

Michael Tomasson, MD  michael-tomasson@uiowa.edu

Mimi McKay, MPH, BSN  mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**MULTIPLE MYELOMA**

**SMOLDERING MYELOMA**

- **Ecog-Acin 173**
  - Phase 3 Pre-emptive tx for high risk smoldering myeloma
  - Dara-Rd x2 years
  - Vs Rd x 2 years
  - "High Risk" SMM = 2 of these:
    - >2.0 g/dl m-protein
    - Cyto: +1q, t[4;14], -17p, -13q
    - >20% PCs in marrow
    - Involved light chains 20x greater than uninvolved
  - Dx in last 1 year, no myeloma defining criteria
  - PI: Christopher Strouse
  - NCT: 03937635

**NEWLY DIAGNOSED**

- **CARTITUDE-6**
  - Phase 3
  - DVRd->Cilta-cel vs DVRd->auto stem cell in first line
  - CT: No prior treatment for MM
  - ASCT is part of intended treatment plan
  - PI: Christopher Strouse
  - NCT05257083

- **S2209**
  - Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance
  - CT: No prior treatment for MM
  - Myeloma Frailty Score= frail or intermediate risk regardless of age
  - PI: Hira Shaikh
  - NCT05561387

- **CARTITUDE-2 Cohort G**
  - Phase 2 evaluation of anti-BCMA CARt cells in first line
  - Dara-RD->Cilta-cel-> no maintenance
  - Up to 2 cycles of Dara-Rd prior to enrollment is allowed (please call us before starting therapy)
  - Transplant deferred OR transplant ineligible patients
  - PI: Christopher Strouse
  - NCT: 04133636

**POST SCT**

- **S1803**
  - Phase 3 evaluation of dara maintenance, and MRD based stopping decision
  - Dara-R vs R maintenance s/p Auto transplant
  - Enrollment within 180 days of transplant, and within 1 year of induction therapy
  - PI: Umar Farooq
  - NCT: 04071457

---

**Clinical Trials Hotline:** 319-353-8155
**Ascorbic Acid + Melphalan**
High Dose Ascorbic Acid is hypothesized to have synergy with melphalan. This is a phase 1 dose escalation trial.
- 3+ prior lines of therapy
- Prior exposure to IMiD, PI, Anti-CD38 antibody required

**Arm 1: Elra + Carf**
1-3 prior lines
Prior carfilzomib is OK

**Arm 2: Elra + anti-CD47**
3+ prior lines of therapy
Refactory to IMiD, PI, anti-CD38 antibody

**C1071020 - Elranatamab + Carfilzomib / anti-CD47 antibody**
Testing combinations with anti-BCMA bispecific antibody.

**P-BCMA-ALLO1**
Allogeneic anti-BCMA CAR-T cells.

**QUINTESSENTIAL**
Autologous anti-GPRC5d CAR-T cells
- Either
  - 2+ prior lines of therapy
  - Refractory to PI, IMiD, anti-CD38 antibody
- 3+ prior lines of therapy
- Exposure to PI, IMiD, anti-CD38 antibody

**LimiTec**
Limited duration therapy of teclistamab
- Patients achieving VGPR or better after 6 cycles of teclistamab (less than 9).
- Telephone consenting and remote monitoring is possible (no need to visit Iowa City)

**MonumenTAL-8**
Combination anti-GPRC5d bispecific antibody + anti-BCMA CAR T cells for high risk myeloma
- 3+ prior lines
- Exposure to IMiD, PI, anti-CD38 antibody
  - "High Risk" myeloma = 1 of:
    - Cyto t[4;14, t[14;16], or -17p
    - Baseline ISS Stage III
    - Extramedullary plasmacytoma
  - No prior anti-BCMA therapy

**Ascorbic Acid + Melphalan**
High Dose Ascorbic Acid is hypothesized to have synergy with melphalan. This is a phase 1 dose escalation trial.
- 3+ prior lines of therapy
- Prior exposure to IMiD, PI, Anti-CD38 antibody required

**Arm 1: Elra + Carf**
1-3 prior lines
Prior carfilzomib is OK

**Arm 2: Elra + anti-CD47**
3+ prior lines of therapy
Refactory to IMiD, PI, anti-CD38 antibody

**C1071020 - Elranatamab + Carfilzomib / anti-CD47 antibody**
Testing combinations with anti-BCMA bispecific antibody.

**P-BCMA-ALLO1**
Allogeneic anti-BCMA CAR-T cells.

**QUINTESSENTIAL**
Autologous anti-GPRC5d CAR-T cells
- Either
  - 2+ prior lines of therapy
  - Refractory to PI, IMiD, anti-CD38 antibody
- 3+ prior lines of therapy
- Exposure to PI, IMiD, anti-CD38 antibody

**LimiTec**
Limited duration therapy of teclistamab
- Patients achieving VGPR or better after 6 cycles of teclistamab (less than 9).
- Telephone consenting and remote monitoring is possible (no need to visit Iowa City)

**MonumenTAL-8**
Combination anti-GPRC5d bispecific antibody + anti-BCMA CAR T cells for high risk myeloma
- 3+ prior lines
- Exposure to IMiD, PI, anti-CD38 antibody
  - "High Risk" myeloma = 1 of:
    - Cyto t[4;14, t[14;16], or -17p
    - Baseline ISS Stage III
    - Extramedullary plasmacytoma
  - No prior anti-BCMA therapy
Sarcoma Trials

Mohammed Milhem, MBBS
mohammed-milhem@uiowa.edu

John Rieth, MD
john-rieth@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**SARCOMA**

**SOFT TISSUE SARCOMA**

**Boast:**
Criteria: Metastatic/LA disease; at least 1 line of prior systemic therapy

**PI:** John Rieth

**NCT:** 04040205

**LEIOMYOSARCOMA**

**Polaris:**
Criteria: Grade 2 or 3 LMS STS that would be standardly treated with gem or gem/doc; previous treatment with up to 2 systemic regimens with at least 1 systemic regimen containing doxorubicin

**PI:** Mohammed Milhem

**NCT:** 05712694

**UNDIFFERENTIATED PLEOMORPHIC**

**Palbociclib + Pembrolizumab**
Criteria: Any patient with locally advanced, unresectable or undifferentiated pleomorphic sarcoma who has progressed on at least 1 prior line of therapy and for whom pembrolizumab is a next appropriate standard treatment.

**PI:** Mohammed Milhem

**NCT:** 0613809

**GIST**

**CGT9486-21-301**
Criteria: Histologically confirmed locally advanced, metastatic, and/or unresectable GIST; documented disease progression or intolerance to imatinib

**PI:** John Rieth

**NCT:** 05208047
SARCOMA

**ANGIOSARCOMA**

IGNYTE
Criteria: locally advanced or metastatic disease; at least 1 measurable and injectable lesion; must have received 8 weeks of anti-PD1 as last line of therapy and progressed while on treatment

Pt: Doug Laux

NCT: 03767348

**BONE SARCOMA**

Gem/Ascorbate:
Criteria: LA, unresectable, or metastatic bone sarcoma from any site; minimum 1 prior chemotherapy regimen; patients eligible for anthracycline should have received anthracycline containing regimen

Pt: John Rieth

NCT03468075

**CHONDROSARCOMA**

INBRX-109
Criteria: Conventional chondrosarcoma, unresectable or metastatic (clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma are not eligible)

Pt: Mohammed Milhem

NCT: 04950075
Thoracic Trials

Muhammad Furqan, MD
muhammad-furqan@uiowa.edu

Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Clinical Trials Hotline: 319-353-8155
NON-SMALL CELL LUNG CANCER

NEOADJUVANT STAGE 1
Ascorbate + Durvalumab
Criteria: Histologically or cytologically confirmed NSCLC; clinical stage I with tumor size > 1 cm to 4 cm (T1b, T1c, T2a and N0M0 per AJCC 8th ed); surgically resectable
PI: Muhammad Furqan
NCT: 06083454

ADJUVANT STAGE 1
BTCRC-LUN18-153
Criteria: Must have undergone complete surgical resection of stage I NSCLC between 4-12 weeks prior to registration and have negative surgical margins (R0); both squamous and non-squamous histologies aloud; pathological tumor size must be 1.0-4.0 cm in greatest dimension
PI: Muhammad Furqan
NCT: 04317534

METASTATIC

1L
Avanzar
Criteria: stage IIIB or IIIC NSCLC not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease; lacks EGFR ALK and ROS1 and no documented tumor genomic alterations in NTRK, BRAF< RET, MET or other actionable driver oncogenes with approved and available therapies
PI: Muhammad Furqan
NCT: 05687266

INBRX-106
Criteria: Locally advanced or metastatic, non-resectable disease which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists
PI: Muhammad Furqan
NCT04198766

2L
Ipat-Lung
Criteria: Advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy and have exhausted/declined or not be candidates for all available SOC therapies
PI: Muhammad Furqan
NCT: 04467801

Clinical Trials Hotline: 319-353-8155
SMALL CELL LUNG CANCER

1L

MOZART:
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules that are too extensive for radiation; No prior systemic therapy for small-cell lung cancer, with the following exceptions: Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study
PI: Muhammad Furqan
NCT05903092

M23-385: Criteria:
Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available
PI: Muhammad Furqan
NCT05999984

2ND LINE+

BGB-A317-A3055-101: Criteria:
Participants with histologically confirmed advanced or metastatic solid tumors associated with high CCR8 and who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and could not receive any prior therapy targeting CCR8
PI: Muhammad Furqan
NCT05935098

BTCRC-LUN20-462
Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy, max of 2 prior lines of systemic therapy in the metastatic setting
PI: Muhammad Furqan
NCT: 04919382

Clinical Trials Hotline: 319-353-8155
Cancer Services – Quad Cities

Shobha Chitneni, MD
Medical Oncologist
shobha-chitneni@uiowa.edu

Mario Sy, MD
Medical Oncologist
mario-sy-1@uiowa.edu

Katy D’Aprile, RN, BSN, OCN
Clinical Trial Coordinator
katherine-daprile@uiowa.edu

Clinical Trials Hotline: 319-353-8155
**THORACIC CANCER**

**NSCLC**

**S2302**
- Criteria: Stage IV or recurrent disease; participants must have received at least one line of anti-PD-1 or anti-PD-L1 therapy for any stage of NSCLC; Participants who received anti-PD-1 or anti-PD-L1 therapy must have had a best stable, partial response or complete response

**Avanzar**
- Criteria: Stage IIIB or IIIC NSCLC not amenable to surgical resection or definitive chemoradiation or Stage IV metastatic disease; lacks EGFR ALK and ROS1 and no documented tumor genomic alterations in NTRK, BRAF< RET, MET or other actionable driver oncogenes with approved and available therapies

**BTCRC-LUN20-462**
- Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

**SCLC**

**MOZART**
- Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules too extensive or have tumor/nodal volume too large for radiation; No prior systemic therapy with the following exceptions:
  - Up to one cycle of platinum doublet chemotherapy +/- durvalumab is allowed up to 4 weeks prior to registration on this study

**PIs:**
- Mario Sy
- Muhammad Furqan

**NCTs:**
- 05633602
- 05687266
- 04919382
- 05903092
Clinical Trials Hotline: 319-353-8155

**BREAST CANCER**

**TRIPLE NEGATIVE**

**Optim-ICE:** T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization

*PI: Sneha Phadke*  
*NCT05812807*

**Cambria:** must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)

*PI: Sneha Phadke*  
*NCT05774951*

**BR009:** premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26

*PI: Sneha Phadke*  
*NCT05879926*
GI CANCER

**COLON**

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing

PI: Saima Sharif

NCT: 05174169

**GEJ**

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif

NCT05677490
MULTIPLE MYELOMA

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx for high risk smoldering myeloma
Dara-Rd x 2 years
Vs
Rd x 2 years

“High Risk” SMM = 2 of these:
- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved
Dx in last 1 year, no myeloma defining criteria
Pt: Christopher Strouse

NCT: 03937635

POST SCT

S1803 Phase 3 evaluation of dara maintenance, and MRD based stopping decision
Dara-R vs R maintenance

s/p Auto transplant
Enrollment within 180 days of transplant, and within 1 year of induction therapy
Pt: Umar Farooq

NCT: 04071457

NEWLY DIAGNOSED

S2209 Phase 3 evaluation comparing up front 3 drug regimens with single or double agent maintenance

No prior treatment for MM
Myeloma Frailty Score = frail or intermediate risk regardless of age
Pt: Hira Shaikh

NCT05561387
LEUKEMIA

ASC2ESCALATE
Criteria: CML-CP, no previous AP or BC

Pi: Mario Sy
NCT05384587